LakeShore Biopharma Co., Ltd (LSB) Stock Analysis & Investment Frameworks
LakeShore Biopharma Co., Ltd (LSB) stock analysis on Invetso. Review LakeShore Biopharma Co., Ltd’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
LakeShore Biopharma Co., Ltd Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: CN
LakeShore Biopharma Co., Ltd Key Financial Metrics
- Market Cap: $25.84M
- Revenue: $92.27M
- ROE: -18.43%
- ROIC: -9.15%
- Dividend Yield: N/A
About LakeShore Biopharma Co., Ltd
LakeShore Biopharma Co., Ltd is a biopharmaceutical firm focused on the discovery, advancement, manufacturing, and marketing of vaccines and therapeutic biologics. Its primary targets are infectious diseases and various forms of cancer. At the core of its innovation is a proprietary PIKA immunomodulating technology platform, which underpins its product pipeline, featuring a PIKA rabies vaccine, a PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. The company maintains an international presence, conducting operations across China, the United States, Singapore, the United Arab Emirates, and the Philippines. Originally founded in 2002 and based in Beijing, China, the entity was known as YS Biopharma Co., Ltd until it officially changed its name to LakeShore Biopharma Co., Ltd in May 2024.